drugset / Trial / NCT06223542
Studying TAK-243 in Patients With Advanced Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase I trial studies the side effects and best dose of ubiquitin-activating enzyme (UAE) inhibitor TAK-243 (TAK-243) in treating patients with a solid tumor that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) and in patients with lymphoma. TAK-243 is a drug that binds to and inhibits the ubiquitin-activating enzyme, an enzyme that is more active on cancer cells than healthy cells, inhibiting tumor cell proliferation and survival.
Timeline
- Start
- 2025-03-24
- Primary completion
- 2027-04-15
- Completion
- 2027-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TAK-243 | Small molecule | — | Intravenous |